About Index Trending news
Analyze
Top 50 Pricing
Amicus Therapeutics

Amicus Therapeutics

Work at Amicus Therapeutics? Add yourself to this profile

Amicus Therapeutics

Biotech

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding
Debt financing
$10,000,000
Venture capital (Series B)
$31,000,000
Employees

Team size

50+
Xconomy

Amicus Takes Aim at Rare Brain Disorder with MiaMed Acquisition

Xconomy

Amicus Nabs First Approval as EU Gives Green Light to Fabry Drug

The Motley Fool

Why Amicus Therapeutics, Inc. Stock Slumped 14.0% in April

The Motley Fool

What Caused Amicus Therapeutics Shares To Skyrocket 23% Last Month

Health Stock markets
The Motley Fool

Amicus Therapeutics Closes In on a 9-Figure Opportunity

The Motley Fool

3 Emerging Biotech Stocks I'm Watching Like a Hawk

The Motley Fool

Why Amicus Therapeutics Shares Are Skyrocketing Again Today

Stock markets
The Motley Fool

Why Amicus Therapeutics Shares Are Up Today

Stock markets
The Motley Fool

Why Amicus Therapeutics Shares Are Soaring 10% Today --

Stock markets Health